Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 12,384 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,384 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total transaction of $426,257.28. Following the completion of the sale, the chief operating officer directly owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. This represents a 14.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL traded down $0.92 during mid-day trading on Wednesday, reaching $34.08. 456,261 shares of the company traded hands, compared to its average volume of 406,528. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The firm has a market cap of $1.04 billion, a PE ratio of -51.64 and a beta of 0.98. The stock has a fifty day simple moving average of $26.45 and a 200-day simple moving average of $25.39.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Equities research analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of CSTL. California State Teachers Retirement System boosted its holdings in shares of Castle Biosciences by 3,176.9% in the second quarter. California State Teachers Retirement System now owns 901,578 shares of the company’s stock worth $21,503,000 after buying an additional 874,065 shares during the period. Empowered Funds LLC acquired a new stake in shares of Castle Biosciences during the second quarter valued at approximately $3,395,000. Jefferies Financial Group Inc. purchased a new stake in shares of Castle Biosciences in the 2nd quarter valued at approximately $15,440,000. Bank of America Corp DE purchased a new stake in shares of Castle Biosciences in the 2nd quarter valued at approximately $2,355,000. Finally, Man Group plc acquired a new position in Castle Biosciences in the 2nd quarter worth approximately $2,594,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

CSTL has been the subject of several research analyst reports. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price objective for the company. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research report on Friday, May 29th. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Finally, Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Castle Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.